Renal Disease and Dialysis
Gregorio P. Milani(Pediatric Oncology Group), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Sander F. Garrelfs(Emma Kinderziekenhuis)
Cited by 0
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope
|Nature Reviews Nephrology|2023|154
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
|Kidney International|2019|103
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria
|Kidney International|2021|90
Genetic assessment in primary hyperoxaluria: why it matters
|Pediatric Nephrology|2022|57